Amphastar Pharmaceuticals (AMPH) Common Equity (2013 - 2026)

Amphastar Pharmaceuticals' Common Equity history runs 14 years deep, the most recent figure standing at $773.4 million for Q1 2026.

• In Q1 2026, Common Equity rose 2.94% year-over-year to $773.4 million; the TTM figure through Mar 2026 stood at $773.4 million (up 2.94% YoY), while the FY2025 annual figure was $788.8 million, up 7.72% from the prior year.
• Common Equity was $773.4 million for Q1 2026 at Amphastar Pharmaceuticals, down from $788.8 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $788.8 million in Q4 2025 to a low of $479.5 million in Q1 2022.
• Historically, Common Equity has averaged $651.7 million across 5 years, with a median of $672.4 million in 2024.
• The sharpest annual moves came in 2024 and 2026: Common Equity advanced 22.56% in 2024, then increased 2.94% in 2026.
• A 5-year view of Common Equity shows it stood at $528.7 million in 2022, then rose by 20.95% to $639.4 million in 2023, then gained by 14.53% to $732.3 million in 2024, then rose by 7.72% to $788.8 million in 2025, then declined by 1.95% to $773.4 million in 2026.
• The last three Common Equity figures came in at $773.4 million (Q1 2026), $788.8 million (Q4 2025), and $776.7 million (Q3 2025), per Business Quant data.